Cargando…

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants

This study assessed the impact of respiratory syncytial virus–confirmed hospitalizations (RSVH) on caregivers of high-risk preterm infants. Caregivers for infants born at 29 to 35 weeks’ gestational age and hospitalized for confirmed RSV disease responded to measures of self-rated and perceived infa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pokrzywinski, Robin M., Swett, Laura L., Pannaraj, Pia S., Yi, Jumi, Pavilack, Melissa S., Kumar, Veena R., McLaurin, Kimmie K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552118/ https://www.ncbi.nlm.nih.gov/pubmed/31007050 http://dx.doi.org/10.1177/0009922819843639

Ejemplares similares

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
por: Lee, Henry, et al.
Publicado: (2017)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012
por: Doucette, Abigail, et al.
Publicado: (2016)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
por: Krilov, Leonard R, et al.
Publicado: (2017)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review
por: Mauskopf, Josephine, et al.
Publicado: (2016)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
por: Arend, Rebecca C., et al.
Publicado: (2021)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants
por: DeVincenzo, John P., et al.
Publicado: (2016)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

Prolonged Seasonality of Respiratory Syncytial Virus Infection among Preterm Infants in a Subtropical Climate
por: Hsu, Chyong-Hsin, et al.
Publicado: (2014)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

IFI27 may predict and evaluate the severity of respiratory syncytial virus infection in preterm infants
por: Gao, Junyan, et al.
Publicado: (2021)

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Respiratory syncytial virus acute respiratory infection‐associated hospitalizations in preterm Mexican infants: A cohort study
por: Benítez‐Guerra, Daniela, et al.
Publicado: (2020)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis
por: Bowser, Diana M, et al.
Publicado: (2022)

Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation
por: Gooch, Katherine L, et al.
Publicado: (2011)

1413. Trends in Risk of Respiratory Syncytial Virus Hospitalizations in Preterm Infants Over a 10-Year Period
por: Kong, Amanda M, et al.
Publicado: (2020)

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma
por: Oh, Chad K, et al.
Publicado: (2013)

The disease burden of respiratory syncytial virus in Infants
por: Munro, Alasdair P.S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibu401768ocgrb5br1uctovgp5